Affymax, Inc. (Nasdaq:AFFY) today announced that Affymax management will host a conference call and webcast at 5:00 p.m. Eastern Time today. The call will discuss the joint Affymax and Takeda decision to focus all development efforts for Hematide™ on the treatment of anemia associated with chronic kidney disease and to suspend co-development of Hematide™ to treat chemotherapy-induced anemia.
Hematide™ is a novel, synthetic pegylated peptide-based erythropoiesis stimulating agent (ESA) that acts on the erythropoietin receptor to stimulate the production of red blood cells. Takeda and Affymax continue to be encouraged by the potential of bringing a convenient, once monthly treatment option to the millions of kidney disease patients suffering from anemia and believe this represents a significant opportunity for the two companies.
Conference Call Details
To access the live conference call today, Thursday, August 28, 2008 at 5:00 p.m. Eastern Time via phone, please dial 877-627-6555 from the United States and Canada or +1-719-325-4893 internationally. The conference ID is 2547088. Please dial in approximately ten minutes prior to the start of the call. Individuals interested in listening to the live call via webcast may do so by visiting www.affymax.com and clicking on the “Investor Relations” section. A replay of the webcast will be available on the Company’s website for 30 days.
About Affymax, Inc.
Affymax, Inc. is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax’s lead product candidate, Hematide™, is currently in Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure. For additional information, please visit www.affymax.com.
This release contains forward-looking statements, including statements regarding the success of the collaboration, timing, design and results of the Company's clinical trials and drug development program and the timing and likelihood of the commercialization of Hematide. The Company's actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including risks relating to the continued safety and efficacy of Hematide in clinical development, the potential for once per month dosing, the timing of patient accrual and treatment in ongoing and planned clinical studies, regulatory requirements and approvals, research and development efforts, industry and competitive environment, intellectual property rights and disputes and other matters that are described in Affymax's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement in this press release.
Contacts:
Sylvia Wheeler, 650-812-8861
Executive Director,
Corporate Communications
